Recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1, N-His

Description of Recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1, N-His

Introduction

The Coxsackievirus A10/CA10 is a common cause of hand, foot, and mouth disease, particularly in children. The virus is a member of the Picornaviridae family and is characterized by its icosahedral capsid structure. The capsid is composed of four structural proteins, including the VP1 protein, which is the most immunogenic and plays a crucial role in viral attachment and entry into host cells. In recent years, recombinant Coxsackievirus A10/CA10 VP1 protein has been studied for its potential as an antigen for vaccine development and diagnostic applications.

Structure of Recombinant Coxsackievirus A10/CA10 VP1 Protein

The VP1 protein of Coxsackievirus A10/CA10 is a 297 amino acid long polypeptide with a molecular weight of approximately 33 kDa. It is composed of three domains, including the N-terminal arm, the body domain, and the C-terminal arm. The N-terminal arm is responsible for receptor binding, while the body domain is involved in virus assembly and stability. The C-terminal arm is responsible for inter-capsomere interactions and is highly conserved among different serotypes of Coxsackievirus. The VP1 protein also contains antigenic sites, which are regions that can induce an immune response in the host.

Activity of Recombinant Coxsackievirus A10/CA10 VP1 Protein

The VP1 protein of Coxsackievirus A10/CA10 is a key component of the virus capsid and plays a crucial role in viral attachment and entry into host cells. It binds to specific receptors on the surface of host cells, such as the coxsackievirus-adenovirus receptor (CAR) and the decay-accelerating factor (DAF). The interaction between the VP1 protein and these receptors triggers a conformational change in the capsid, allowing the virus to enter the host cell. Additionally, the VP1 protein is highly immunogenic and can induce a strong immune response in the host, making it a potential target for vaccine development.

Application of Recombinant Coxsackievirus A10/CA10 VP1 Protein

Vaccine Development

The VP1 protein of Coxsackievirus A10/CA10 has been studied as a potential antigen for vaccine development against hand, foot, and mouth disease. Recombinant VP1 protein can be produced in large quantities using recombinant DNA technology, making it a feasible option for vaccine production. Studies have shown that immunization with recombinant VP1 protein can induce a strong immune response and protect against Coxsackievirus A10/CA10 infection in animal models. Furthermore, the VP1 protein is highly conserved among different serotypes of Coxsackievirus, making it a potential candidate for a broad-spectrum vaccine against multiple serotypes.

Diagnostic Applications

The VP1 protein of Coxsackievirus A10/CA10 has also been studied for its potential use in diagnostic assays. Recombinant VP1 protein can be used as an antigen in serological tests to detect the presence of antibodies against the virus in patient samples. This can aid in the diagnosis of Coxsackievirus A10/CA10 infection and help in monitoring the spread of the virus. Additionally, the VP1 protein can also be used in molecular diagnostic assays, such as polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR), for the detection of viral RNA in patient samples.

Therapeutic Applications

Recombinant VP1 protein has also been investigated for its potential therapeutic applications. Studies have shown that the VP1 protein can bind to and neutralize the virus, preventing its entry into host cells. This suggests that recombinant VP1 protein could potentially be used as a therapeutic agent for